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Abstract: Accumulating evidence within the last two decades indicates the association between cardiovascular disease 
(CVD) and chronic inflammatory state. Under normal conditions fibrin clots are gradually degraded by the fibrinolytic 
enzyme system, so no permanent insoluble deposits remain in the circulation. However, fibrinolytic therapy in coronary 
and cerebral thrombosis is ineffective unless it is installed within 3-5 hours of the onset. We have shown that trivalent iron 
(FeIII) initiates a hydroxyl radical-catalyzed conversion of fibrinogen into a fibrin-like polymer (parafibrin) that is 
remarkably resistant to the proteolytic dissolution and thus promotes its intravascular deposition. Here we suggest that the 
persistent presence of proteolysis-resistant fibrin clots causes chronic inflammation. We study the effects of certain 
amphiphilic substances on the iron- and thrombin-induced fibrinogen polymerization visualized using scanning electron 
microscopy. We argue that the culprit is an excessive accumulation of free iron in blood, known to be associated with 
CVD. The only way to prevent iron overload is by supplementation with iron chelating agents. However, administration 
of free radical scavengers as effective protection against persistent presence of fibrin-like deposits should also be 
investigated to contribute to the prevention of cardiovascular and other degenerative diseases. 
Keywords: Cardiovascular disease, fibrinogen, free radicals, inflammation, iron, parafibrin, thrombosis. 
INTRODUCTION 
 Numerous epidemiological and large prospective studies 
have shown that hypercoagulability [1] and the increased 
blood level of fibrinogen (FBG) are important risk factors 
for cardiovascular disease [2-4]. It is generally agreed that 
the higher content of fibrinogen in plasma the greater the 
chance of thrombus formation, therefore its level should be 
maintained as low as possible. It should be remembered, 
however, that critical factor in thrombosis is not the absolute 
amount of FBG, but the fate of its thrombin-generated 
product, fibrin. Under physiological conditions fibrin clots 
are gradually, albeit completely, removed from the site of 
vessel wall injury by the powerful fibrinolytic system of 
blood [5]. 
 However, if for some reason the fibrinolytic system is 
inefficient, persisting thrombi will obstruct the flow of blood 
with all its pathological consequences. The best example of 
such a situation is the use of a thrombin-like enzyme of viper 
venom (Ancrod) for the prevention of thrombosis [6]. Thus, 
despite a complete conversion of all circulating FBG to 
fibrin, no persistent thrombi are produced due to the solid 
phase activation of fibrinolysis by fibrin [7]. Disseminated 
intravascular thrombosis occur only when fibrinolysis is 
inhibited by eg. Aprotinin [8]. 
 The presence of fibrin-like material in atherosclerotic 
plaques was first observed over 150 years ago by Karl  
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Rokitansky [8] and later confirmed by other researchers [1, 
9-11]. In 1995 Elspeth Smith documented the existence of 
fibrinogen-related antigens (FRA) the insoluble fraction 
obtained from atherosclerotic intima [12]. According to this 
author FRA is present at the surface as well as deep inside 
the plaques thus providing scaffolding for migration and 
proliferation of smooth muscle cells. It should be 
emphasized that this type of insoluble FGB deposits are 
morphologically different from fibrin present in thrombi 
formed as a result of plaque raptures [13]. This fact obscures 
identification of fibrin-like material present inside the 
arterial wall, and may perhaps explain why the attention of 
researches were drawn away and directed to a more popular 
concept of the role of cholesterol [14]. 
 The presence of insoluble FBG deposits in 
atherosclerotic plaques was also attempted to be explained 
by the loss of negative charge of the arterial wall of subjects 
with CVD. It was demonstrated that the amount of acid 
mucopolysaccharides (AMPS) extractable from the arterial 
intima was significantly lower in CVD patients as compared 
to young and healthy subjects [15]. According to this idea 
AMPS would form soluble complexes with blood fibrin 
monomers thus preventing their anchoring and deposition on 
the endothelial cells. However, this mechanism would 
require a chronic activation of intravascular blood 
coagulation that has still to be proven. 
THE ROLE OF IRON 
 Although atherosclerosis is also known to be associated 
with the inhibition of fibrinolysis, no specific mechanism 
and/or agent(s) have been identified. Studies by Undas and 
collaborators shed some light on this problem by showing 
that the susceptibility of fibrin clot to lysis is affected by the 
structure and permeability of fibrin network [16]. This 
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phenomenon is compatible with the observed thrombolytic 
resistance in patients with coronary and/or cerebral 
thrombosis [17]. 
 Another important fact is that there is a relationship 
between body iron overload and pathogenesis of numerous 
degenerative diseases, including atherosclerosis [18-23]. 
Particularly relevant is the extensive review by D.B.Kell on 
the role of free blood iron in various pathological conditions. 
[24]. In addition, links have been found to exist between iron 
body stores, cardiovascular risk factors and hypercoa-
gulability [25, 26]. Moreover, in experimental models the 
infusion of trivalent iron salts was shown to cause diffused 
thrombosis [27]. It is a common belief that free blood iron, 
via the Fenton-like reaction, is responsible for so-called 
oxidative stress that, in turn, leads to atherosclerosis and 
related cardiovascular diseases [28]. Yet, despite this 
attractive, albeit simplistic, concept no effectiveness of 
antioxidant therapy has been demonstrated [29]. As a result 
numerous natural products (specifically polyphenols) are not 
being clinically tried because they had been labeled as 
antioxidants. This highly controversial and, in fact, 
damaging notion was dealt with in a recent article, which 
emphasized the importance of polyphenolic substances as 
iron chelating and free radical scavenging agents that may be 
neither oxidants nor antioxidants [30]. 
Iron-Induced Conversion of Fibrinogen to Parafibrin 
 We have recently documented that trivalent iron ion 
(FeIII) generates in aqueous solutions powerful hydroxyl 
radicals that subsequently modify fibrinogen molecules 
converting them to insoluble fibrin-like polymer [31]. It 
should be emphasized that such a polymer is not only 
resistant to fibrinolytic dissolution, but also to proteolytic 
digestion, i.e. with chymotrypsin, that normally degrades 
fibrin(ogen) into smaller polypeptide fragments. Protein 
chemistry teaches us that undesirable molecular interactions 
in blood proteins are prevented by holding their hydrophobic 
groups inside the interior of protein tridimensional structures 
stabilized by intra-molecular disulfide bonds. Once these 
bonds are broken the polypeptide chains become unfolded 
with the exposure of hydrophobic domains which form inter-
molecular bonds resulting in the formation of large 
aggregates. It is of great importance to note that such 
aggregates cannot be degraded by the proteolytic enzymes as 
is the case with human prion proteins [32] and bacterial 
hydrophobins [33]. Consequently, it is often very difficult to 
identify insoluble fibrin deposits in pathologically affected 
organs in various chronic diseases, because no antigen can 
be released into the liquid phase of the extracted tissues. In 
concordance with this, the presence of insoluble fibrin(ogen) 
deposits can only be demonstrated by a direct 
immunochemical staining of the tissue sections. 
Parafibrin as an Inflammation Inducer 
 The resistance of fibrin clots to enzymatic degradation 
can now be explained by our finding of the alternative iron-
induced mechanism of blood coagulation (Fig. 1). According 
to this concept free iron of blood (Fe III) generates hydroxyl 
radicals, which in turn convert circulating FBG into an 
insoluble fibrin-like material ( or parafibrin) without the 
action of thrombin [31]. It should be strongly emphasized 
that this pseudo or parafibrin is one of very few proteins, 
such as prions [32] and bacterial hydrophobins [33], that are 
totally resistant to enzymatic proteolysis. As a consequence 
such a dense fibrin polymer acquires the features of a foreign 
body and attracts macrophages resulting in a permanent state 
of inflammation known to be associated with atherosclerosis 
[34-37]. Also it is of interest to note the reports on the 
relationship between inflammation and blood coagulation. 
Moreover there are numerous experimental and clinical 
studies that indicate the relationship between inflammation, 
iron overload and cardiovascular diseases [20, 38-40]. 
Protective Mechanisms Against Iron-Induced Pathology 
 As shown in Fig. (1) the intravascular formation of 
modified fibrin can be inhibited at two stages. First, and 
perhaps the most important, is the inactivation of free iron, 
usually achievable by the administration of a variety of iron 
chelators [24, 41-47], as well as by other means of the 
reduction of body iron stores [48]. If this fails, the next step 
is elimination of hydroxyl radicals by means of a number of 
natural and/or synthetic scavengers. The hydroxyl radical 
scavenging reaction occurs by virtue of aromatic 
hydroxylation, as exemplified by the reaction with salicylic 
acid known to prevent inflammation and its consequences 
[47]. This reaction is believed to be responsible for the 
beneficial health effects of polyphenolic substances present 
in fruits and vegetables of the so-called Mediterranean diet 
[49]. Small molecular weight phenolic compounds such as 
chlorogenic acid, ferulic and coumaric acids, consumed with 
certain food products, become even more effective hydroxyl 
radical scavengers due to their enhanced absorption from the 
alimentary track. The larger molecules of polyphenols have 
to be first metabolized by the intestinal flora (probiotics) in 
order to achieve their in vivo health beneficial effect [50]. 
 In concert with this observation it is the fact that the 
altered fibrin structure argued to be associated with 
cardiovascular disease (CVD) can be normalized by the 
pretreatment with hydrophilic substances e.g. high-density 
lipoprotein (HDL) [51] and/or human serum albumin known 
to be decreased in CVD [52-55]. The protective effect of 
such substances is documented here using SEM method for 
HDL (Fig. 2C), and for a non-ionic detergent Tween 20 (Fig. 
2A and B). These results stand in contrast with the 
potentiation of iron-induced dense parafibrin formation 
exerted by low density lipoprotein (Fig. 2D). It is also 
possible that the health beneficial effect of human serum 
albumin (HSA), a highly hydrophilic protein, is due to the 
restoration of normal fibrin strands generated with thrombin 
(Fig. 2E and F). Therefore, it can be concluded that it is not 
just iron homeostasis, but the blood content of hydrophilic 
and polyphenolic agents that is important in the prevention 
of atherosclerosis. 
THE ROLE OF RED BLOOD CELLS 
 Another pathologic process leading to atherosclerosis is 
the impaired blood flow caused by the intravascular 
aggregation of red blood cells (RBC). Although its 
mechanism is not completely understood, it is well known 
that the elevated erythrocyte sedimentation rate (ESR)  
is associated with inflammation and CVD. (56-59) We have  
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Fig. (1). Conversion of plasma fibrinogen into insoluble polymers catalyzed by thrombin (left panel), and the formation of dense fibrin 
deposits generated with iron (right panel). By contrast to the enzymatically formed fibrin susceptible to fibrinolysis, the iron-induced fibrin 
polymer is remarkably resistant to proteolytic degradation. Reprinted with permission from Pol Arch Med Wewn. Vol.122, p.120 (Fig.6), 
2012. 31 
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Fig. (2). Effects of certain amphiphilic substances on the iron- and thrombin-induced fibrinogen (FGB) polymerization visualized USING 
scanning electron microscopy, A. Control: Purified fibrinogen (PF) and ferric chloride (FC); B. PF + Tween 20 + FC ; C. PF + high-density 
lipoprotein + FC; D. PF + low-density lipoprotein + FC; E. Low-albumin plasma (LAP)+ thrombin; F. LAP + purified human albumin + 
thrombin; G. Whole blood of a stroke patient; H. Normal whole blood + FC. Scale = 1 µm. 
 
shown for the first time that the abnormal RBC morphology 
induced by iron ions added to normal blood is strikingly 
similar to that observed in blood of stroke patients [60] as 
well as of subjects with diabetes mellitus  [61]. These 
changes are shown here in Fig. (2G) (Stroke) and H (healthy 
blood with added ferric iron). It is argued that the close 
association between RBC and the modified fibrinogen 
molecules can be caused by the interaction between 
hydrophobic epitopes on the cell membranes and those of the 
soluble fibrin protofibrils generated with iron (Fig. 1). This 
mechanism may explain significant reduction of blood flow 
[62] and increased blood viscosity in patients with 
thrombotic arterial disease [63]. The relationship between 
inflammation and elevated ESR was emphasized years ago 
by Zacharski and Kyle [64]. Finally, it should be noted that 
RBC aggregation and sedimentation were originally thought 
to be caused by blood soluble fibrin monomers by virtue of 
their interaction with hydrophobic epitopes on RBC 
membranes [65]. However, this concept was abandoned in 
view of the absence of any evidence of the link between 
chronic activation of intravascular blood coagulation and 
ESR. The concept of iron-induced parafibrin formation 
offers more plausible mechanism of the relationship between 
hemorheologic disturbances and inflammation. 
CONCLUSION 
 In conclusion, we postulate in this paper that the excess 
of blood free iron is responsible for the non-enzymatic 
generation of insoluble fibrin-like material (parafibrin) that, 
when deposited on the arterial wall, initiates inflammatory 
reactions. This pathological process, very different from the 
classical activation of blood coagulation, can be prevented 
by substances that chelate iron, scavenge hydroxyl radicals, 
and inhibit hydrophobic interactions in proteins. However, in 
view of the fact that, so far, there is no known agent or a 
biological process that can degrade parafibrin, an 
interdisciplinary research approach is needed to find an 
effective method for the elimination from the human body 
this unique inducer of chronic inflammation. 
ETHICAL APPROVAL DISCLOSURE 
 Ethical approval was granted at the University of Pretoria 
(Human Ethics Committee: Faculty OF Health Sciences) 
under the name of E Pretorius (corresponding author). All 
human blood samples obtained were analyzed at the 
University of Pretoria and all participants filled in informed 
consent forms. 
CONFLICT OF INTEREST 
 The authors confirm that this article content has no 
conflicts of interest. 
ACKNOWLEDGEMENTS 
 The authors would like to thank Natasha Vermeulen and 
Janette Bester for technical assistance with sample 
preparation. 
REFERENCES 
[1]  Chan MY, Andreotti F, Becker RC. Hypercoagulable states in 
cardiovascular disease. Circulation. 2008;118(22):2286-97. Epub 
2008/11/26. 
[2]  Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen 
and risk of cardiovascular disease. The Framingham Study. JAMA. 
1987;258(9):1183-6. Epub 1987/09/04. 
Iron-Induced Fibrin in Cardiovascular Disease Current Neurovascular Research, 2013, Vol. 10, No. 3     273 
[3]  Levenson J, Giral P, Razavian M, Gariepy J, Simon A. Fibrinogen 
and silent atherosclerosis in subjects with cardiovascular risk 
factors. Arterioscler Thromb Vasc Biol. 1995;15(9):1263-8. Epub 
1995/09/01. 
[4]  Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, 
Gao P, et al. C-reactive protein, fibrinogen, and cardiovascular 
disease prediction. N Engl J Med. 2012;367(14):1310-20. Epub 
2012/10/05. 
[5]  Astrup T. The biological significance of fibrinolysis. Lancet. 
1956;271(6942):565-8. Epub 1956/09/15. 
[6]  Liu S, Marder VJ, Levy DE, Wang SJ, Yang F, Paganini-Hill A, et 
al. Ancrod and fibrin formation: perspectives on mechanisms of 
action. Stroke. 2011;42(11):3277-80. Epub 2011/08/27. 
[7]  Lipinski B, Nowak A, Gurewich V. The organ distribution of 125I-
fibrin in the generalized Shwartzman reaction and its relation to 
leucocytes. Br J Haematol. 1974;28(2):221-31. Epub 1974/10/01. 
[8]  Rokitansky K. A Manual of Pathological Anatomy 1852;Vol.IV. 
London: Sydenham Society. 
[9]  Duguid JB. Thrombosis as a factor in the pathogenesis of coronary 
atherosclerosis. J Pathol Bacteriol. 1946;58:207-12. Epub 
1946/04/01. 
[10]  Kadish JL. Fibrin and atherogenesis--a hypothesis. Atherosclerosis. 
1979;33(4):409-13. Epub 1979/08/01. 
[11]  Bini A, Kudryk BJ. Fibrinogen and fibrin in the arterial wall. 
Thromb Res. 1994;75(3):337-41. Epub 1994/08/01. 
[12]  Smith EB. Fibrinogen, fibrin and the arterial wall. Eur Heart J. 
1995;16 Suppl A:11-4; discussion 4-5. Epub 1995/03/01. 
[13]  Ogata J, Yutani C, Kaneko T, Kuriyama Y, Sawada T. Rupture of 
atheromatous plaque as a cause of thrombotic occlusion of the 
internal carotid artery. Stroke. 1987;18(6):1175-6. Epub 
1987/11/01. 
[14]  Bennett PC, Silverman SH, Gill PS, Lip GY. Peripheral arterial 
disease and Virchow's triad. Thromb Haemost. 2009;101(6):1032-
40. Epub 2009/06/06. 
[15]  Lipinski B, Lewicki Z, Zajdel M, Miks B, Hagel E. Saline 
extractable acid mucopolysaccharides of human aorta in relation to 
age, sex and atherosclerosis. Mater Med Pol. 1972;4(1):19-22. 
Epub 1972/01/01. 
[16]  Undas A, Szuldrzynski K, Stepien E, Zalewski J, Godlewski J, 
Tracz W, et al. Reduced clot permeability and susceptibility to lysis 
in patients with acute coronary syndrome: effects of inflammation 
and oxidative stress. Atherosclerosis. 2008;196(2):551-7. Epub 
2007/07/21. 
[17]  Lipinski B. Modification of fibrin structure as a possible cause of 
thrombolytic resistance. J Thromb Thrombolysis. 2010;29(3):296-
8. Epub 2009/06/25. 
[18]  Ahluwalia N, Genoux A, Ferrieres J, Perret B, Carayol M, Drouet 
L, et al. Iron status is associated with carotid atherosclerotic 
plaques in middle-aged adults. J Nutr. 2010;140(4):812-6. Epub 
2010/02/26. 
[19]  Brewer GJ. Iron and copper toxicity in diseases of aging, 
particularly atherosclerosis and Alzheimer's disease. Exp Biol Med 
(Maywood). 2007;232(2):323-35. Epub 2007/01/30. 
[20]  Depalma RG, Hayes VW, Chow BK, Shamayeva G, May PE, 
Zacharski LR. Ferritin levels, inflammatory biomarkers, and 
mortality in peripheral arterial disease: a substudy of the Iron (Fe) 
and Atherosclerosis Study (FeAST) Trial. J Vasc Surg. 
2010;51(6):1498-503. Epub 2010/03/23. 
[21]  Hahalis G, Kalogeropoulos A, Terzis G, Tselepis AD, Kourakli A, 
Mylona P, et al. Premature atherosclerosis in non-transfusion-
dependent beta-thalassemia intermedia. Cardiology. 
2011;118(3):159-63. Epub 2011/06/08. 
[22]  Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron 
stores and the risk of carotid atherosclerosis: prospective results 
from the Bruneck study. Circulation. 1997;96(10):3300-7. Epub 
1997/12/13. 
[23]  Merono T, Rosso LG, Sorroche P, Boero L, Arbelbide J, Brites F. 
High risk of cardiovascular disease in iron overload patients. Eur J 
Clin Invest. 2011;41(5):479-86. Epub 2010/12/07. 
[24]  Kell DB. Towards a unifying, systems biology understanding of 
large-scale cellular death and destruction caused by poorly liganded 
iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, 
chemical toxicology and others as examples. Arch Toxicol. 
2010;84(11):825-89. Epub 2010/10/23. 
[25]  Franchini M, Targher G, Montagnana M, Lippi G. Iron and 
thrombosis. Ann Hematol. 2008;87(3):167-73. Epub 2007/12/11. 
[26]  Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, 
Salonen R. High stored iron levels are associated with excess risk 
of myocardial infarction in eastern Finnish men. Circulation. 
1992;86(3):803-11. Epub 1992/09/01. 
[27]  Tian J, Hu S, Sun Y, Ban X, Yu H, Dong N, et al. A novel model 
of atherosclerosis in rabbits using injury to arterial walls induced 
by ferric chloride as evaluated by optical coherence tomography as 
well as intravascular ultrasound and histology. J Biomed 
Biotechnol. 2012;2012:121867. Epub 2012/06/06. 
[28]  Griendling KK, FitzGerald GA. Oxidative stress and 
cardiovascular injury: Part I: basic mechanisms and in vivo 
monitoring of ROS. Circulation. 2003;108(16):1912-6. Epub 
2003/10/22. 
[29]  Steinhubl SR. Why have antioxidants failed in clinical trials? Am J 
Cardiol. 2008;101(10A):14D-9D. Epub 2008/06/24. 
[30]  Lipinski B. Hydroxyl radical and its scavengers in health and 
disease. Oxid Med Cell Longev. 2011;2011:809696. Epub 
2011/09/10. 
[31]  Lipinski B, Pretorius E. Novel pathway of ironinduced blood 
coagulation: implications for diabetes mellitus and its 
complications. Pol Arch Med Wewn. 2012;122(3):115-22. Epub 
2012/03/31. 
[32]  Das D, Luo X, Singh A, Gu Y, Ghosh S, Mukhopadhyay CK, et al. 
Paradoxical role of prion protein aggregates in redox-iron induced 
toxicity. PLoS ONE. 2010;5(7):e11420. Epub 2010/07/14. 
[33]  Kwan AH, Winefield RD, Sunde M, Matthews JM, Haverkamp 
RG, Templeton MD, et al. Structural basis for rodlet assembly in 
fungal hydrophobins. Proc Natl Acad Sci U S A. 
2006;103(10):3621-6. Epub 2006/03/16. 
[34]  Kleemann R, Verschuren L, Morrison M, Zadelaar S, van Erk MJ, 
Wielinga PY, et al. Anti-inflammatory, anti-proliferative and anti-
atherosclerotic effects of quercetin in human in vitro and in vivo 
models. Atherosclerosis. 2011;218(1):44-52. Epub 2011/05/24. 
[35]  Libby P. Inflammation in atherosclerosis. Arterioscler Thromb 
Vasc Biol. 2012;32(9):2045-51. Epub 2012/08/17. 
[36]  Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 
1999;340(2):115-26. Epub 1999/01/14. 
[37]  Hansson GK. Inflammation, atherosclerosis, and coronary artery 
disease. N Engl J Med. 2005;352(16):1685-95. Epub 2005/04/22. 
[38]  Hu FB. The iron-heart hypothesis: search for the ironclad evidence. 
JAMA. 2007;297(6):639-41. Epub 2007/02/15. 
[39]  Menke A, Fernandez-Real JM, Muntner P, Guallar E. The 
association of biomarkers of iron status with peripheral arterial 
disease in US adults. BMC Cardiovasc Disord. 2009;9:34. Epub 
2009/08/05. 
[40]  Lele S, Shah S, McCullough PA, Rajapurkar M. Serum catalytic 
iron as a novel biomarker of vascular injury in acute coronary 
syndromes. EuroIntervention. 2009;5(3):336-42. Epub 2009/09/09. 
[41]  Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, 
Keaney JF, Jr., et al. Iron chelation improves endothelial function 
in patients with coronary artery disease. Circulation. 
2001;103(23):2799-804. Epub 2001/06/13. 
[42]  Ferrara DE, Taylor WR. Iron chelation and vascular function: in 
search of the mechanisms. Arterioscler Thromb Vasc Biol. 
2005;25(11):2235-7. Epub 2005/11/01. 
[43]  Kwiatkowski JL. Oral iron chelators. Hematol Oncol Clin North 
Am. 2010;24(1):229-48. Epub 2010/02/02. 
[44]  Matthews AJ, Vercellotti GM, Menchaca HJ, Bloch PH, Michalek 
VN, Marker PH, et al. Iron and atherosclerosis: inhibition by the 
iron chelator deferiprone (L1). J Surg Res. 1997;73(1):35-40. Epub 
1998/02/14. 
[45]  Zhang WJ, Wei H, Frei B. The iron chelator, desferrioxamine, 
reduces inflammation and atherosclerotic lesion development in 
experimental mice. Exp Biol Med (Maywood). 2010;235(5):633-
41. Epub 2010/05/14. 
[46]  Yuan XM, Li W. The iron hypothesis of atherosclerosis and its 
clinical impact. Ann Med. 2003;35(8):578-91. Epub 2004/01/08. 
[47]  Mehta SR. Aspirin for prevention and treatment of cardiovascular 
disease. Ann Intern Med. 2009;150(6):414-6. Epub 2009/03/19. 
[48]  Zacharski LR, Shamayeva G, Chow BK. Effect of controlled 
reduction of body iron stores on clinical outcomes in peripheral 
arterial disease. Am Heart J. 2011;162(5):949-57 e1. Epub 
2011/11/19. 
[49]  Nadtochiy SM, Redman EK. Mediterranean diet and 
cardioprotection: the role of nitrite, polyunsaturated fatty acids, and 
polyphenols. Nutrition. 2011;27(7-8):733-44. Epub 2011/04/02. 
274     Current Neurovascular Research, 2013, Vol. 10, No. 3 Lipinski and Pretorius 
[50]  Kahle K, Huemmer W, Kempf M, Scheppach W, Erk T, Richling 
E. Polyphenols are intensively metabolized in the human 
gastrointestinal tract after apple juice consumption. J Agric Food 
Chem. 2007;55(26):10605-14. Epub 2007/12/01. 
[51]  Zabczyk M, Hondo L, Krzek M, Undas A. High-density cholesterol 
and apolipoprotein AI as modifiers of plasma fibrin clot properties 
in apparently healthy individuals. Blood Coagul Fibrinolysis. 2012. 
Epub 2012/10/06. 
[52]  Alvarez-Perez FJ, Castelo-Branco M, Alvarez-Sabin J. Albumin 
level and stroke. Potential association between lower albumin level 
and cardioembolic aetiology. Int J Neurosci. 2011;121(1):25-32. 
Epub 2010/10/20. 
[53]  Folsom AR, Lutsey PL, Heckbert SR, Cushman M. Serum albumin 
and risk of venous thromboembolism. Thromb Haemost. 
2010;104(1):100-4. Epub 2010/04/15. 
[54]  Hostmark AT, Tomten SE. Serum albumin and self-reported 
prevalence of stroke: a population-based, cross-sectional study. Eur 
J Cardiovasc Prev Rehabil. 2006;13(1):87-90. Epub 2006/02/02. 
[55]  Kim KJ, Yang WS, Kim SB, Lee SK, Park JS. Fibrinogen and 
fibrinolytic activity in CAPD patients with atherosclerosis and its 
correlation with serum albumin. Perit Dial Int. 1997;17(2):157-61. 
Epub 1997/03/01. 
[56]  Andresdottir MB, Sigfusson N, Sigvaldason H, Gudnason V. 
Erythrocyte sedimentation rate, an independent predictor of 
coronary heart disease in men and women: The Reykjavik Study. 
Am J Epidemiol. 2003;158(9):844-51. Epub 2003/10/31. 
[57]  Erikssen G, Liestol K, Bjornholt JV, Stormorken H, Thaulow E, 
Erikssen J. Erythrocyte sedimentation rate: a possible marker of 
atherosclerosis and a strong predictor of coronary heart disease 
mortality. Eur Heart J. 2000;21(19):1614-20. Epub 2000/09/16. 
[58]  Nagy E, Eaton JW, Jeney V, Soares MP, Varga Z, Galajda Z, et al. 
Red cells, hemoglobin, heme, iron, and atherogenesis. Arterioscler 
Thromb Vasc Biol. 2010;30(7):1347-53. Epub 2010/04/10. 
[59]  Natali A, L'Abbate A, Ferrannini E. Erythrocyte sedimentation rate, 
coronary atherosclerosis, and cardiac mortality. Eur Heart J. 
2003;24(7):639-48. Epub 2003/03/27. 
[60]  Lipinski B, Pretorius E, Oberholzer HM, van der Spuy WJ. 
Interaction of fibrin with red blood cells: the role of iron. 
Ultrastruct Pathol. 2012;36(2):79-84. Epub 2012/04/05. 
[61]  Pretorius E, Lipinski B. Iron alters red blood cell morphology. 
Blood. 2013;121(1):9. 
[62]  Arbel Y, Banai S, Benhorin J, Finkelstein A, Herz I, Halkin A, et 
al. Erythrocyte aggregation as a cause of slow flow in patients of 
acute coronary syndromes. Int J Cardiol. 2012;154(3):322-7. Epub 
2011/07/26. 
[63]  Cairncross D, Collins GM, Kostalas G, Ludbrook J. Blood 
viscosity and erythrocyte sedimentation rate in patients with 
thrombotic arterial disorders. Med J Aust. 1969;1(26):1348-52. 
Epub 1969/06/28. 
[64]  Zacharski LR, Kyle RA. Significance of extreme elevation of 
erythrocyte sedimentation rate. JAMA. 1967;202(4):264-6. Epub 
1967/10/23. 
[65]  Lipinski B, Worowski K, Mysliwiec M, Farbiszewski R. 
Erythrocyte sedimentation and soluble fibrin monomer complexes. 
Thromb Diath Haemorrh. 1969;21(2):196-202. Epub 1969/04/30. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PMID: 23721262 
